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Motor neuron diseases (MNDs) are a rather heterogeneous group of diseases, with either sporadic or genetic origin or both, all
characterized by the progressive degeneration of motor neurons. At the cellular level, MNDs share features such as protein mis-
foldingandaggregation,mitochondrialdamageandenergydeﬁcit,andexcitotoxicityandcalciummishandling.Thisisparticularly
well demonstrated in ALS, where both sporadic and familial forms share the same symptoms and pathological phenotype, with
a prominent role for mitochondrial damage and resulting oxidative stress. Based on recent data, however, altered control of gene
expression seems to be a most relevant, and previously overlooked, player in MNDs. Here we discuss which may be the links that
make pathways apparently as diﬀerent as altered gene expression, mitochondrial damage, and oxidative stress converge to generate
a similar motoneuron-toxic phenotype.
1.Introduction
Motor neuron diseases (MNDs) are a rather heterogeneous
group of diseases, with either sporadic or genetic origin or
both, all characterized by the progressive degeneration of
motor neurons. All MNDs are primarily axonopathies of the
motor neurons in which neuromuscular synapses are early
targets of damage and death of motor neurons probably
occurs following loss of the neuromuscular junctions [1].
MNDs may manifest as weakness, atrophy of muscles, dif-
ﬁculty in breathing, speaking, and swallowing, with symp-
toms and severity varying as a consequence of the diﬀerent
involvement of upper or lower motor neurons or both.
The most common and studied form in adults is Amyo-
trophic Lateral Sclerosis (ALS), followed by Progressive Bul-
bar Palsy (PBP), the rarer forms being Progressive Muscular
Atrophy (PMA) and Primary Lateral Sclerosis (PLS). These
conditions seem to form a continuum of diseases since only
part of patients have a “pure” phenotype, while others with
PBP or PLS eventually develop the widespread symptoms
common to ALS [2]. In all these MNDs, onset of symptoms
occurs mainly in people aged 40–70. Life expectancy is
between2toabout5yearsafteronsetinALSand6monthsto
3 years in PBP, while pure PLS patients may have a normal or
near-to-normal life duration. MNDs also include Spinal and
BulbarMuscularAtrophy(SBMA),inwhichageofonsetand
severity of manifestations vary from adolescence to old age,
but longevity is usually not compromised. Infantile MNDs
include Spinal Muscular Atrophy (SMA) with an infantile or
juvenile onset and Lethal Congenital Contracture Syndrome
(LCCS), causing prenatal death and thus being the most
severe form of motor neuron disease.
2.Aetiology ofMNDs
LCCS1isanautosomalrecessiveconditionfoundincommu-
nitiesofthenortheasternpartofFinlandwithaprevalenceof
1in25,250births[3].LCCSmanifestsinuterowithamarked
atrophy of spinal cord motor neurons and fetal immobility
due to lack of anterior horn motor neurons, severe atrophy
oftheventralspinal cord,andhypoplastic skeletal muscles.It
is characterized by total immobility of the fetus, detectable at
the13thweekofpregnancyandinvariablyleadingtoprenatal2 International Journal of Cell Biology
death before the 32nd gestational week. The defective gene
for LCCS1 is a 16-exon gene coding for GLE1, an mRNA
export mediator that is known to interact with the nuclear
pore complex and is expressed in the neural tube of 11-day-
old mice embryos, speciﬁcally in the ventral cell population
from which the motor neurons diﬀerentiate, and later in
other tissues including somites, from which skeletal muscle
and bone tissue diﬀerentiate [3]. The most frequent muta-
tion in LCCS1 (FinMajor) does not dramatically alter the
stability or localization of the protein GLE1 but is predicted
to introduce three aminoacid residues in a region that may
be critical in the interaction between GLE1 and a motor
neuron-speciﬁc protein [3].
SMA is the most frequent genetic cause of infant mortal-
ity and exists in various forms invariably caused by a genetic
defect.Patientswiththemostcommonform(proximalSMA)
areeitherdeletedforthenine-exongeneSMN1,encodingthe
ubiquitously expressed protein SMN (Survival Motor Neu-
ron) or carry small mutations in the same gene. However,
SMA patients always carry at least one copy of the gene
SMN2, which encodes the same protein as SMN1 and is
only partially functional because of a critical, translationally
silent single nucleotide C/T transition inside exon 7 that pro-
foundly aﬀects correct splicing. The clinical severity of SMA
ranges from respiratory distress at birth associated with
limitedlifeexpectancy(SMA1)toonsetatolderthan10years
and a normal life expectancy (SMA4) and is inversely related
to the level of SMN2 compensating for SMN1 deletion [4].
SBMA (also called Kennedy’s disease) is an X-linked
recessive motor neuron disease in which only lower spinal
cordandbrainstemmotor neuronsareaﬀected[5].SBMAis
caused by a polyglutamine expansion in the androgen recep-
tor (AR) [6]; CAG repeat numbers range from 38 to 62 in
SBMA patients, whereas healthy individuals have 10 to 36
CAG repeats. Symptoms appear in childhood or early ad-
olescence [7]; SBMA is a rare disease, with the exception
of some population in the Vasa region of Western Finland
where it was estimated that the prevalence is 13 in 85,000
male inhabitants [8].
While SMA, SBMA, and LCCS1 are invariably familial
diseases, adult-onset MNDs are both sporadic and familial.
PBP, PMA, and PLS are usually sporadic. ALS occurs sporad-
ically in the majority of cases [9]. Proposed risk factors for
ALS include ingestion of high concentrations of β-methyl-
amino-L-alanine [10], use of cholesterol-lowering drugs
[11], intensive physical exercise [12] including football
playing [13, 14] and service in the USA Army [15], possibly
linked to intermittent occupational hypoxia [16]o rt oh e a d
injury [17–19]. Environmental factors also include cigarette
smoking [18, 20], exposure to heavy metals [21], and pesti-
cidesorherbicides[22–24].Approximately10%ofALScases
isinherited,withmultipleautosomaldominantandrecessive
forms that have been ascribed to mutations in a number
of diﬀerent genes, each of them accounting for a diﬀerent
percentage of cases (Table 1). Interestingly, ALS-associated
mutated proteins are implicated in a wide range of cellular
processes, from antioxidant response to axonal and vesicular
transport, angiogenesis, endoplasmic reticulum (ER) stress
and unfolded protein response (UPR), and, most noticeably,
to RNA metabolism.
3.Multifactorialityof MNDs:
The Role of AlteredGeneExpression
At the cellular level, MNDs share features such as protein
misfolding and aggregation, mitochondrial damage and
energy deﬁcit, excitotoxicity, and calcium mishandling [1], a
condition often indicated as multifactoriality. This is partic-
ularly well demonstrated in ALS, where both sporadic and
familial forms share the same symptoms and pathological
phenotype, that are recapitulated in available animal and cell
models, with a prominent role for mitochondrial damage
and resulting oxidative stress (for an extended Review, see
[25]). Oxidative stress is reported also in SMA [26]a n dr e a c -
tive oxygen species (ROS) inhibit assembly and activity of
SMN complex in a dose-dependent manner [27]. Mitochon-
drial damage seems to be invariably present in neurodegen-
erative conditions [28] including SMA [29–32]a n dS B M A
[33], in which mitochondrial dysfunction may be due to the
interaction between AR and cytochrome c oxidase subunit
Vb (COXVb) [34].
Based on recent data, however, altered control of gene
expression seems to be a most relevant, and previously
overlooked, player in MNDs.
Severalstudiesaddressingepigeneticmodiﬁcations,tran-
scriptomics, and proteomics of models and tissues from
patients indicate that the overall pattern of gene expression
is modiﬁed in MNDs. Because of the known non-cell auto-
nomous mechanism of death of motor neurons, studies in
ALS have been performed in tissues [35, 36] and in neuronal
and in nonneuronal cultured cells (astrocytes, muscle) and
revealed that most of the deregulated genes are involved in
defense responses, cytoskeletal dynamics, protein degrada-
tion system, and mitochondrial dysfunction in neurons [37],
while the insulin-like growth factor-1 receptor and the RNA-
binding protein ROD1 are the most downregulated genes
in glia [38]. The pattern is altered also in muscle, in which
many of deregulated genes are the same found in surgically
denervated muscles, while others appear to be ALS-speciﬁc
and include proteins clearly involved in the redox response
(e.g., metallothionein-2 and thioredoxin-1) [39, 40]. In a
recent proteomic study on embryonic stem cell from a severe
SMA mouse model diﬀerentiated into motor neurons in
vitro, Wu et al. reported that 6 proteins are downregulated
and 14 upregulated in this model. Most of these proteins
belong to the same categories altered in ALS models, that
is, are involved in energy metabolism, cell stress response,
protein degradation, and cytoskeleton stability [41].
As in other neurodegenerative conditions, alterations of
transcription in MNDs may follow altered epigenetic control
due to an unbalance between histone acetyl transferases
(HATs)andhistonedeacetylases(HDACs,includingsirtuins,
SIRTs) activities [42]. These enzymes catalyze forward and
reverse reactions of lysine residue acetylation; thus, HATs
modify core histone tails thereby enhancing DNA accessi-
bility to transcription factors (TFs), while HDACs activity
in general results in transcriptional repression and gene
silencing. Interestingly, various TFs, like RelA, E2F, p53, and
GATA1, which form part of the transcription initiation com-
plex, are themselves substrates susceptible to the action of
HATs and HDACs.International Journal of Cell Biology 3
Table 1: Genes involved in MNDs.
Gene Protein MND Main known function
SOD1 Cu, Zn superoxide dismutase ALS1 Antioxidant enzyme
ALS2 Alsin ALS2 guanine nucleotide exchange factor for GTPases
SETX Senataxin ALS4 DNA/RNA metabolism and repair
SPG11 Spataxin ALS5 Neuron diﬀerentiation and axonal transport
FUS/TLS Fused in sarcoma ALS6 RNA binding protein
VAPB VAMP-associated protein B ALS8 Traﬃcking between the endoplasmic reticulum and
Golgi apparatus
TDP-43 TAR-DNA-binding protein-43 ALS9 DNA- and RNA-binding protein
ANG Angiogenin ALS10 Angiogenesis in response to hypoxia; possibly RNA
metabolism
FIG4 PI(3,5)P(2)5-phosphatase ALS11 Metabolism of phosphatidyl inositol bisphosphate and
vesicle dynamic
OPTN Optineurin ALS12 Vesicular traﬃcking
nAChR Neuronal nicotinic
acetylcholine receptor ALS Glutamatergic pathway
CHMP2B Charged multivesicular
protein 2B ALS Chromatin-modifying protein/charged multivesicular
body protein family
VCP Valosin-containing protein ALS Membrane traﬃcking, organelle biogenesis,
maturation of ubiquitin-containing autophagosomes
DAO D-aminoacid oxidase ALS Oxidative deamination of D-aminoacid
UBQLN2 Ubiquilin2 ALS Ubiquitin-proteasome response
Sig-1R Sigma-1 receptor ALS ER chaperone, modulates calcium signaling through
the IP3 receptor
C9ORF72 Unknown ALS Unknown
AR Androgen receptor SBMA Androgen receptor
SMN Survival Motor Neuron SMA RNA processing
GLE1 Nucleoporin GLE1 LCCS1 Export of mRNAs containing poly(A)
Evidence for the involvement of this kind of regulation
in MNDs is accumulating, although still far from deﬁnitive,
and unspeciﬁc HDAC inhibitors such as sodium phenylbu-
tyrate, trichostatin A, and valproic acid have been tested as
neuroprotective drugs for the treatment of ALS with some
positive result [43–47]. It is interesting to note that valproic
acid is also endowed with antioxidative and antiapoptotic
properties.However,mostlikelyonlyselectedHDACspartic-
ipate to onset or propagation of motor neuron damage and
thus must be targeted for an eﬀective therapy. This concept
is strengthened by the observation that complexes formed
by ALS-linked proteins TDP-43 and FUS/TLS control the
expression level of HDAC6 [48].
The SMN gene has a reproducible pattern of histone
acetylation that is largely conserved among diﬀerent tissues
and species [49] and several HDAC pan-inhibitors such as
suberoylanilide hydroxamic acid (SAHA) [50], trichostatin
A[ 51], and the benzamide M344 [52] increase SMN2 trans-
cript and protein levels. Valproic acid is currently tested in
phase I and II clinical trials for the treatment of SMA (http://
clinicaltrials.gov/). However, valproic acid has also serious
adverse eﬀects in cell and mice models for SMA [53, 54]
pointing again to the need of inhibition of selected HDACs
in MNDs, especially in the light of a recent report that the
SMN2 gene is diﬀerentially regulated by individual HDAC
proteins and silencing of HDAC5 and 6 enhances inclusion
of an alternatively spliced exon in SMN2 [55]. Finally, oral
administration of the HDAC inhibitor sodium butyrate has
been tested also in a transgenic mouse model of SBMA with
some positive outcome but only within a narrow range of
drug dosage [56].
Epigenetic control of transcription may also occur via
methylation by DNA methyltransferases (DNMTs) or his-
tone methyltransferases (HMTs), both using S-adenosylme-
thionine (SAM o AdoMet) as the methyl donor. DNA meth-
ylation in eukaryotes occurs by the covalent modiﬁcation of
cytosine residues (on the ﬁfth carbon) in CpG dinucleotides,
leading to gene silencing. Methylation of histones (as well as
transcription factors) occurs on lysine or arginine. Methy-
lated lysine residues can carry up to three methyl moieties on
their amine group, whereas arginine can be mono- or dim-
ethylated on the guanidinyl group. Lysine methylation of
histones is associated with activation or repression of trans-
cription, depending on the degree of methylation and on the
residue location [57].
Methylation may be extremely relevant in MNDs if one
considers, for instance, that recognition of some Sm proteins
by the SMN complex (that mediates the assembly of the Sm
proteins onto snRNAs involved in pre-mRNA splicing and
histone mRNA processing) is dependent on symmetrical4 International Journal of Cell Biology
dimethyl arginine modiﬁcations of their RG-rich tails [58,
59]. This methylation is achieved by PRMT(protein arginine
methyltransferase) 5 or by PRMT7, two enzymes that func-
tion nonredundantly [60] and utilize SAM as methyl donor.
Furthermore, the SMN2 gene is subject to gene silencing
by DNA methylation and some HDAC inhibitors including
vorinostat and romidepsin are able to bypass SMN2 gene
silencing by DNA methylation, while others such as valproic
acid and phenylbutyrate are not [61].
Other observations support the concept that MNDs may
be considered as “RNA dysmetabolisms” [62]. As reported
in Table 1, several of the genetic factors involved in MNDs
encode proteins with a role in RNA metabolism, and some
overlap may exist among diﬀerent diseases. For instance,
copy number abnormalities of the SMN genes have been
reported in sporadic ALS, although decrease of SMN protein
in the anterior horn cells of ALS patients may be only a
secondaryphenomenon[63,64].RNAmetabolism,however,
consists of several intertwined steps, such as pre-mRNA
splicing, mRNA transport, translational regulation, or
mRNAdecay,andthepreciseRNApathwaythatisaﬀectedin
a single MND remains unknown because virtually every one
of the involved RNA-binding proteins has been implicated in
more than one of these steps. Thus, it is not clear why motor
neurons are so vulnerable to mutations in RNA-binding
proteins.
Very recently, familial ALS has been associated with an
expansion of a noncoding GGGGCC hexanucleotide repeat
in the gene C9ORF72 [65, 66] that codes for an unknown
protein. The transcribed GGGGCC repeat forms intracellu-
lar accumulations of RNA fragments in cells in the frontal
cortex and the spinal cord from patients carrying the expan-
sion [65]. These RNA foci are composed of the expanded
nucleotide repeats that may disturb transcription by seques-
tering RNA-binding proteins involved in transcription regu-
lation as observed for other expanded RNA repeats diseases
[67] such as myotonic dystrophy [68]. Interestingly, the
GGGGCC sequence also represents a potential binding site
of several RNA-binding proteins including hnRNP A2/B1, a
TDP-43 interactor [69, 70].
4. Altered Gene Expression,
MitochondrialDamage, andOxidativeStress
inMNDs: WhichArethe Links?
Which are the links among altered gene expression, mito-
chondrial damage, and oxidative stress in MNDs is not clear
yet. While oxidative stress and mitochondrial dysfunction
are obviously connected into a vicious cycle in which excess
in ROS production may inﬂuence the functionality of the
organelles, that in turn would produce excess ROS, the con-
nection with altered gene expression in MNDs is still some-
what foggy.
A few considerations may help to shed some light on
possible, not mutually exclusive, mechanisms.
In analogy to what has been proposed in development
[71] and in cancer [72], an interplay among oxidative stress,
thiol redox signaling, and epigenetic modulation by methy-
lation may be critical in motor neurons. The antioxidant
capacity of cells is inﬂuenced by the production of glu-
tathione (GSH), and increased GSH production inﬂuences
DNA and histone methylation by limiting the availability of
SAM, the cofactor utilized during epigenetic control of gene
expression by DNA and histone methyltransferases [71]. The
a b o v em e n t i o n e df o r m so fm e t h y l a t i o n ,w h i c ha r er e l e v a n t
in MNDs, are not directly linked, since they involve diﬀerent
enzymes and diﬀerent targets. However, they all require the
same methyl donor, which could be limiting in MNDs.
HDACs themselves seem to be linked to and modulated
byoxidativestress.Pan-HDACinhibitionpromotesneuronal
protection against oxidative stress in a model of glutathione
depletion [73], thus suggesting that HDACs are downstream
mediator in the mechanisms of toxicity by ROS, while
carbonylation of reactive cysteines of some, but not all, class
I HDACs causes reduction of histone deacetylase activity and
change in histones acetylation and transcription of genes
repressed by these HDACs [74]. Thus, oxidative stress may
be a modulator of gene expression through the modulation
of DNA accessibility.
In turn, the activity of HDACs modulates alternative
splicing of human genes when the nascent RNA is still asso-
ciated with chromatin (in particular the splicing of hundreds
of genes is altered upon HDAC inhibition) [75] but also the
activity of various TFs. Noticeably, oxidative stress is also a
modulator of several TFs and thus ROS and HDACs may
concur in the generation of a pathological phenotype
through the same mechanism. For instance, as reviewed by
Rahman et al. [76], oxidative stress inhibits HDAC activity
and activates HAT activity; this leads to NF-κBa c t i v a -
tion, which, in turn activates proinﬂammatory mediators.
The antioxidant and/or anti-inﬂammatory eﬀects of thiol
molecules (GSH, N-acetyl-L-cysteine and Nacystelyn) and
dietary polyphenols (e.g., curcumin and resveratrol) have a
role in either the control of NF-κB activation or the mod-
ulation of HDAC. Thus, oxidative stress may regulate both
TFs and chromatin remodeling which in turn impacts on
proinﬂammatory responses.
Furthermore,SIRTs(classIIIHDACs)controltheexpres-
sion or the activity of a number of proteins involved in
redox regulation (Table 2). Among these proteins, some are
mitochondrial and many have been involved in one or more
MNDs by transcriptomic/proteomic studies [77–79].
Last, but not the least, we have reported that mitochon-
drial damage itself is a cause of modiﬁcation in the abun-
dance of selected splicing variants [80] and that defective
RNA metabolism seems to play a role also in SOD1-linked
ALS and to descend directly from mitochondrial stress [81].
5. A UnifyingMechanismfor MNDs?
From what summarized above, it is tempting to speculate
that indeed all MNDs are mainly forms of RNA dysmetab-
olisms. Motor neurons seem to be exceedingly susceptible
to defects in RNA transcription or processing; one appealing
explanationisthattheyrequirethatRNAisnotonlycorrectlyInternational Journal of Cell Biology 5
Table 2: Eﬀects of class II HDACs (Sirtuins) on redox-related proteins.
Sirtuin Target Eﬀect Reference
SIRT1 (nucleus and mitochondria)
FOXO3a ↑ Transcriptional activity [82]
PGC-1α ↑ Transcriptional coactivation [83, 84]
HIF1α ↓ Transcriptional activity [85]
HIF2α ↑ Transcriptional activity [86]
eNOS ↑ Enzyme activity [87]
p53 Mediates transcriptional activity,
depending on SIRT1 expression level [88, 89]
SIRT2 (cytoplasm) FOXO3a ↑ Transcriptional activity [90]
SIRT3 (mitochondria)
HIF1α ↓ Transcriptional activity [91]
SOD2 ↑ Enzyme activity [92, 93]
OTC ↑ Enzyme activity [94]
NDUFA9 ↑ Enzyme activity [95]
GDH ↑ Enzyme activity [96]
IDH2 ↑ Enzyme activity [97]
SIRT4 (mitochondria) GDH ↓ Enzyme activity [98]
SIRT5 (mitochondria) CPS1 ↑ Enzyme activity [99]
SIRT6 (mitochondria) HIF1α ↓ Transcriptional activity [100]
SIRT7 (nucleoli) p53 Mediates transcriptional activity,
depending on SIRT7 expression level [101]
CPS1: carbamoyl phosphate synthetase 1; eNOS: endothelial nitric oxide synthase; FOXO3a: Forkhead box O3 a; GDH: glutamate dehydrogenase; HIF1α:
hypoxia-inducible factor 1, alpha subunit; HIF2α: hypoxia-inducible factor 2, alpha subunit; IDH2: isocitrate dehydrogenase 2; NDUFA9: NADH dehydroge-
nase [ubiquinone] 1 alpha subcomplex subunit 9; OTC: ornithine transcarbamylase; PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator
1-alpha; SOD2: superoxide dismutase 2.
transcribed and spliced, but also correctly transported along
axons to neuromuscular junctions (NMJ). While there is no
clear demonstration of the presence of mRNAs at the NMJs
yet, this process (at least in ALS) might resent from the
known alterations in axonal transport that precedes onset of
symptoms [102].
However, one form or the other of alteration of RNA
expression may have diﬀerent weight in diﬀerent MNDs and,
most importantly, RNA dysmetabolisms may be a primary
event (for instance in SMA or in TDP43- and FUS/TLS-
linked ALS) or dysregulation of components of the genetic
machinery (the HATs/HDACs system, transcription factors,
the splicing complex) may be secondary to oxidative stress
or energy failure. In turn, which step is the primary site of
damage may dictate the severity of disease (age of onset, pro-
gression), and which cell type beside motor neurons is pri-
marily aﬀected may dictate the form of MND. This ﬁeld
surely deserves further investigation aimed to the individu-
ation of novel therapeutic approaches for MNDs.
Abbreviations
ALS: Amyotrophic lateral sclerosis
ALS2: Alsin
ANG: Angiogenin
AR: Androgen receptor
CHMP2B: Charged multivesicular protein 2B
COXVb: Cytochrome c oxidase subunit Vb
DAO: D-amino acid oxidase
DNMT: DNA methyltransferase
ER: Endoplasmic reticulum
FIG4: PI(3,5)P(2)5-phosphatase
FUS/TLS: Fused in sarcoma/translocated in
liposarcoma
GLE1: Nucleoporin GLE1
GSH: Glutathione
HAT: Histone acetyl transferase
HDAC: Histone deacetylase
HMT: Histone methyltransferase
LCCS: Lethal congenital contracture syndrome
MND: Motor neuron disease
nAChR: Neuronal nicotinic acetylcholine receptor
OPTN: Optineurin;
PBP: Progressive bulbar palsy
PLS: Primary lateral sclerosis
PMA: Progressive muscular atrophy
PRMT5: Protein arginine methyltransferase 5
PRMT7: Protein arginine methyltransferase 7
ROS: Reactive oxygen species
SAHA: Suberoylanilide hydroxamic acid
SAM: S-adenosylmethionine
SBMA: Spinal and bulbar muscular atrophy
SETX: Senataxin
Sig-1R Sigma: 1 receptor6 International Journal of Cell Biology
SIRT: Sirtuin
SMA: Spinal muscular atrophy
SMN: Survival motor neuron
SOD1: Cu, Zn superoxide dismutase
SPG11: Spataxin
TDP-43: TAR DNA-binding protein 43
TF: Transcription factor
UBQLN2: Ubiquilin 2
UPR: Unfolded protein response
VAPB: VAMP-associated protein
VCP: Valosin-containing protein.
Acknowledgments
L. Rossi research is supported by Grants from MIUR (PRIN
2008J2LRWZ); M. T. Carr` ı research is supported by Grants
from MIUR (PRIN 20083R593R), IMI-San Paolo and ERA-
Net Neuron.
References
[1] S. Saxena and P. Caroni, “Selective neuronal vulnerability
in neurodegenerative diseases: from stressor thresholds to
degeneration,” Neuron, vol. 71, no. 1, pp. 35–48, 2011.
[2] M. J. Strong and P. H. Gordon, “Primary lateral sclerosis, he-
reditary spastic paraplegia and amyotrophic lateral sclerosis:
discrete entities or spectrum?” Amyotrophic Lateral Sclerosis
and Other Motor Neuron Disorders, vol. 6, no. 1, pp. 8–16,
2005.
[3] H. O. Nousiainen, M. Kestil¨ a, N. Pakkasj¨ arvi et al., “Muta-
tions in mRNA export mediator GLE1 result in a fetal moto-
neuron disease,” Nature Genetics, vol. 40, no. 2, pp. 155–157,
2008.
[4] M. R. Lunn and C. H. Wang, “Spinal muscular atrophy,” The
Lancet, vol. 371, no. 9630, pp. 2120–2133, 2008.
[5] G. Sobue, Y. Hashizume, E. Mukai, M. Hirayama, T. Mit-
suma, and A. Takahashi, “X-linked recessive bulbospinal
neuronopathy. A clinicopathological study,” Brain, vol. 112,
part 1, pp. 209–232, 1989.
[6] A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding,
and K. H. Fischbeck, “Androgen receptor gene mutations in
X-linked spinal and bulbar muscular atrophy,” Nature, vol.
352, no. 6330, pp. 77–79, 1991.
[ 7 ]A .D .S p e r f e l d ,J .K a r i t z k y ,D .B r u m m e re ta l . ,“ X - l i n k e d
bulbospinal neuronopathy: Kennedy disease,” Archives of
Neurology, vol. 59, no. 12, pp. 1921–1926, 2002.
[8] B. Udd, V. Juvonen, L. Hakamies et al., “High prevalence of
Kennedy’s disease Western Finland—is the syndrome under-
diagnosed?” Acta Neurologica Scandinavica,v o l .9 8 ,n o .2 ,p p .
128–133, 1998.
[9] P. N. Valdmanis, H. Daoud, P. A. Dion, and G. A. Rouleau,
“Recent advances in the genetics of amyotrophic lateral scle-
rosis,” CurrentNeurology andNeuroscienceReports,vol. 9, no.
3, pp. 198–205, 2009.
[10] P. A.Cox and O. W. Sacks, “Cycad neurotoxins, consumption
of ﬂying foxes, and ALS-PDC disease in Guam,” Neurology,
vol. 58, no. 6, pp. 956–959, 2002.
[11] B. A. Golomb, E. K. Kwon, S. Koperski, and M. A. Evans,
“Amyotrophic lateral sclerosis-like conditions in possible
association with cholesterol-lowering drugs: an analysis of
patient reports to the University of California, San Diego
(UCSD) statin eﬀects study,” Drug Safety,v o l .3 2 ,n o .8 ,p p .
649–661, 2009.
[12] C. A. Harwood, C. J. McDermott, and P. J. Shaw, “Physical
activity as an exogenous risk factor in motor neuron disease
(MND): a review of the evidence,” Amyotrophic Lateral Scle-
rosis, vol. 10, no. 4, pp. 191–204, 2009.
[13] A. Chi` o, G. Benzi, M. Dossena, R. Mutani, and G. Mora, “Se-
verely increased risk of amyotrophic lateral sclerosis among
Italian professional football players,” Brain, vol. 128, part 3,
pp. 472–476, 2005.
[14] P. Wicks, J. Ganesalingham, C. Collin, M. Prevett, N. P.
Leigh, and A. Al-Chalabi, “Three soccer playing friends with
simultaneous amyotrophic lateral sclerosis,” Amyotrophic
Lateral Sclerosis, vol. 8, no. 3, pp. 177–179, 2007.
[15] E. J. Kasarskis, J. H. Lindquist, C. J. Coﬀman et al., “Clinical
aspects of ALS in Gulf War Veterans,” Amyotrophic Lateral
Sclerosis, vol. 10, no. 1, pp. 35–41, 2009.
[ 1 6 ]N .V a n a c o r e ,P .C o c c o ,D .F a d d a ,a n dM .D o s e m e c i ,“ J o b
strain, hypoxia and risk of amyotrophic lateral sclerosis:
results from a death certiﬁcate study,” Amyotrophic Lateral
Sclerosis, vol. 11, no. 5, pp. 430–434, 2010.
[ 1 7 ]H .C h e n ,M .R i c h a r d ,D .P .S a n d l e r ,D .M .U m b a c h ,a n d
F. Kamel, “Head injury and amyotrophic lateral sclerosis,”
American Journal of Epidemiology, vol. 166, no. 7, pp. 810–
816, 2007.
[18] S. Schmidt, L. C. Kwee, K. D. Allen, and E. Z. Oddone, “Asso-
ciationofALSwithheadinjury,cigarettesmokingandAPOE
genotypes,” Journal of the Neurological Sciences, vol. 291, no.
1-2, pp. 22–29, 2010.
[19] A. C. McKee et al., “TDP-43 proteinopathy and motor neu-
ron disease in chronic traumatic encephalopathy,” Journal of
Neuropathology and Experimental Neurology, vol. 69, no. 9,
pp. 918–929, 2010.
[20] V. Gallo, H. B. Bueno-De-Mesquita, R. Vermeulen et al.,
“Smoking and risk for amyotrophic lateral sclerosis: analysis
of the EPIC cohort,” Annals of Neurology,v o l .6 5 ,n o .4 ,p p .
378–385, 2009.
[21] F. Kamel, D. M. Umbach, H. Hu et al., “Lead exposure as a
risk factor for amyotrophic lateral sclerosis,” Neurodegenera-
tive Diseases, vol. 2, no. 3-4, pp. 195–201, 2005.
[22] B. R. Brooks, “Risk factors in the early diagnosis of ALS:
North American epidemiological studies,” Amyotrophic Lat-
eral Sclerosis and Other Motor Neuron Disorders, vol. 1,
supplement 1, pp. S19–S26, 2000.
[23] C. J. Burns, K. K. Beard, and J. B. Cartmill, “Mortality
in chemical workers potentially exposed to 2,4-dichloro-
phenoxyacetic acid (2,4-D) 1945-94: an update,” Occupa-
tional and Environmental Medicine, vol. 58, no. 1, pp. 24–30,
2001.
[24] N. A. Sutedja, J. H. Veldink, K. Fischer et al., “Exposure to
chemicals and metals and risk of amyotrophic lateral sclero-
sis:asystematicreview,”AmyotrophicLateralSclerosis,vol.10,
no. 5-6, pp. 302–309, 2009.
[25] M. Cozzolino and M. T. Carri, “Mitochondrial dysfunction
in ALS,” Progress in Neurobiology, vol. 97, no. 2, pp. 54–66,
2012.
[26] M. Hayashi, S. Araki, N. Arai et al., “Oxidative stress and
disturbed glutamate transport in spinal muscular atrophy,”
Brain and Development, vol. 24, no. 8, pp. 770–775, 2002.
[27] L. Wan, E. Ottinger, S. Cho, and G. Dreyfuss, “Inactivation
of the SMN complex by oxidative stress,” Molecular Cell, vol.
31, no. 2, pp. 244–254, 2008.International Journal of Cell Biology 7
[28] E. A. Schon and S. Przedborski, “Mitochondria: the next
(Neurode)generation,”Neuron,vol.70,no.6,pp.1033–1053,
2011.
[29] A. Berger, J. A. Mayr, D. Meierhofer et al., “Severe depletion
of mitochondrial DNA in spinal muscular atrophy,” Acta
Neuropathologica, vol. 105, no. 3, pp. 245–251, 2003.
[30] S. Jongpiputvanich, T. Sueblinvong, and T. Norapucsunton,
“Mitochondrial respiratory chain dysfunction in various
neuromuscular diseases,” Journal of Clinical Neuroscience,
vol. 12, no. 4, pp. 426–428, 2005.
[31] G. Acsadi, I. Lee, X. Li et al., “Mitochondrial dysfunction in
a neural cell model of spinal muscular atrophy,” Journal of
Neuroscience Research, vol. 87, no. 12, pp. 2748–2756, 2009.
[32] T. Voigt, K. Meyer, O. Baum, and D. Sch¨ umperli, “Ultra-
structural changes in diaphragm neuromuscular junctions
in a severe mouse model for Spinal Muscular Atrophy and
theirpreventionbybifunctionalU7snRNAcorrectingSMN2
splicing,” Neuromuscular Disorders, vol. 20, no. 11, pp. 744–
752, 2010.
[33] S. Ranganathan, G. G. Harmison, K. Meyertholen, M.
Pennuto, B. G. Burnett, and K. H. Fischbeck, “Mitochon-
drial abnormalities in spinal and bulbar muscular atrophy,”
Human Molecular Genetics, vol. 18, no. 1, pp. 27–42, 2009.
[34] A. M. J. Beauchemin, B. Gottlieb, L. K. Beitel, Y. A. Elhaji, L.
Pinsky, and M. A. Triﬁro, “Cytochrome c oxidase subunit Vb
interacts with human androgen receptor: a potential mech-
anism for neurotoxicity in spinobulbar muscular atrophy,”
Brain Research Bulletin, vol. 56, no. 3-4, pp. 285–297, 2001.
[35] A. Malaspina, N. Kaushik, and J. de Belleroche, “Diﬀerential
expression of 14 genes in amyotrophic lateral sclerosis spinal
cord detected using gridded cDNA arrays,” Journal of Neuro-
chemistry, vol. 77, no. 1, pp. 132–145, 2001.
[36] C. W. Lederer, A. Torrisi, M. Pantelidou, N. Santama, and S.
Cavallaro,“Pathwaysandgenesdiﬀerentiallyexpressedinthe
motor cortex of patients with sporadic amyotrophic lateral
sclerosis,” BMC Genomics, vol. 8, article 26, 2007.
[37] F.Tanakaetal.,“Neuropathologyandomicsinmotorneuron
diseases,” Neuropathology. In press.
[ 3 8 ]M .R .V a r g a s ,M .P e h a r ,P .J .D ´ ıaz-Amarilla, J. S. Beckman,
and L. Barbeito, “Transcriptional proﬁle of primary astro-
cytes expressing ALS-linked mutant SOD1,” Journal of Neu-
roscience Research, vol. 86, no. 16, pp. 3515–3525, 2008.
[39] J. L. Gonzalez de Aguilar, C. Niederhauser-Wiederkehr, B.
Halter et al., “Gene proﬁling of skeletal muscle in an amyo-
trophic lateral sclerosis mouse model,” Physiological Genom-
ics, vol. 32, no. 2, pp. 207–218, 2008.
[40] P. F. Pradat et al., “Muscle gene expression is a marker of
amyotrophic lateral sclerosis severity,” Neuro-Degenerative
Diseases, vol. 9, no. 1, pp. 38–52, 2012.
[41] C.Y.Wu,D.Whye,L.Glazewskietal.,“Proteomicassessment
of a cell model of spinal muscular atrophy,” BMC Neuro-
science, vol. 12, article 25, 2011.
[42] R. N. Saha and K. Pahan, “HATs and HDACs in neurodegen-
eration: A tale of disconcerted acetylation homeostasis,” Cell
Death and Diﬀerentiation, vol. 13, no. 4, pp. 539–550, 2006.
[43] S. Petri, M. Kiaei, K. Kipiani et al., “Additive neuroprotective
eﬀects of a histone deacetylase inhibitor and a catalytic
antioxidant in a transgenic mouse model of amyotrophic
lateral sclerosis,” Neurobiology of Disease,v o l .2 2 ,n o .1 ,p p .
40–49, 2006.
[44] M. E. Cudkowicz, P. L. Andres, S. A. Macdonald et al., “Phase
2 study of sodium phenylbutyrate in ALS,” Amyotrophic
Lateral Sclerosis, vol. 10, no. 2, pp. 99–106, 2009.
[45] F. Sugai, Y. Yamamoto, K. Miyaguchi et al., “Beneﬁt of val-
proic acid in suppressing disease progression of ALS model
mice,” European Journal of Neuroscience, vol. 20, no. 11, pp.
3179–3183, 2004.
[46] H. L. Feng, Y. Leng, C. H. Ma, J. Zhang, M. Ren, and D. M.
Chuang, “Combined lithium and valproate treatment delays
disease onset, reduces neurological deﬁcits and prolongs
survival in an amyotrophic lateral sclerosis mouse model,”
Neuroscience, vol. 155, no. 3, pp. 567–572, 2008.
[47] Y. E. Yoo and C. P. Ko, “Treatment with trichostatin A ini-
tiated after disease onset delays disease progression and in-
creases survival in a mouse model of amyotrophic lateral
sclerosis,” Experimental Neurology, vol. 231, no. 1, pp. 147–
159, 2011.
[48] S. H. Kim, N. P. Shanware, M. J. Bowler, and R. S. Tibbetts,
“Amyotrophic lateral sclerosis-associated proteins TDP-43
and FUS/TLS function in a common biochemical complex
to co-regulate HDAC6 mRNA,” The Journal of Biological
Chemistry, vol. 285, no. 44, pp. 34097–34105, 2010.
[49] L. E. Kernochan, M. L. Russo, N. S. Woodling et al., “The
role of histone acetylation in SMN gene expression,” Human
Molecular Genetics, vol. 14, no. 9, pp. 1171–1182, 2005.
[50] E. Hahnen, I. Y. Ey¨ upoglu, L. Brichta et al., “In vitro and
ex vivo evaluation of second-generation histone deacetylase
inhibitors for the treatment of spinal muscular atrophy,”
Journal of Neurochemistry, vol. 98, no. 1, pp. 193–202, 2006.
[51] A. M. Avila, B. G. Burnett, A. A. Taye et al., “Trichostatin
A increases SMN expression and survival in a mouse model
of spinal muscular atrophy,” Journal of Clinical Investigation,
vol. 117, no. 3, pp. 659–671, 2007.
[52] M. Riessland, L. Brichta, E. Hahnen, and B. Wirth, “The
benzamide M344, a novel histone deacetylase inhibitor,
signiﬁcantly increases SMN2 RNA/protein levels in spinal
muscular atrophy cells,” Human Genetics, vol. 120, no. 1, pp.
101–110, 2006.
[53] K. Rak, B. D. Lechner, C. Schneider, H. Drexl, M. Sendtner,
and S. Jablonka, “Valproic acid blocks excitability in SMA
type I mouse motor neurons,” Neurobiology of Disease, vol.
36, no. 3, pp. 477–487, 2009.
[54] H. R. Fuller, N. T. Man, L. T. Lam, V. A. Shamanin, E.
J. Androphy, and G. E. Morris, “Valproate and bone loss:
iTRAQproteomicsshowthatvalproatereducescollagensand
osteonectin in SMA cells,” Journal of Proteome Research, vol.
9, no. 8, pp. 4228–4233, 2010.
[ 5 5 ]M .C .E v a n s ,J .J .C h e r r y ,E .J .A n d r o p h ye ta l . ,“ D i ﬀerential
regulation of the SMN2 gene by individual HDAC proteins,”
Biochemical and Biophysical Research Communications, vol.
414, no. 1, pp. 25–30, 2011.
[56] M. Minamiyama, M. Katsuno, H. Adachi et al., “Sodium
butyrate ameliorates phenotypic expression in a transgenic
mouse model of spinal and bulbar muscular atrophy,”
Human Molecular Genetics, vol. 13, no. 11, pp. 1183–1192,
2004.
[57] S. L. Berger, “The complex language of chromatin regulation
during transcription,” Nature, vol. 447, no. 7143, pp. 407–
412, 2007.
[58] O. Tapia, R. Bengoechea, M. T. Berciano, and M. Lafarga,
“Nucleolar targeting of coilin is regulated by its hypomethy-
lation state,” Chromosoma, vol. 119, no. 5, pp. 527–540, 2010.
[59] K. Tripsianes, “Structural basis for dimethylarginine recog-
nition by the Tudor domains of human SMN and SPF30
proteins,” Nature Structural & Molecular Biology, vol. 18, no.
12, pp. 1414–1420, 2011.8 International Journal of Cell Biology
[60] G. B. Gonsalvez, L. Tian, J. K. Ospina, F. M. Boisvert, A. I.
Lamond, and A. G. Matera, “Two distinct arginine methyl-
transferases are required for biogenesis of Sm-class ribonu-
cleoproteins,” Journal of Cell Biology, vol. 178, no. 5, pp. 733–
740, 2007.
[61] J. Hauke, M. Riessland, S. Lunke et al., “Survival motor
neuron gene 2 silencing by DNA methylation correlates with
spinal muscular atrophy disease severity and can be bypassed
by histone deacetylase inhibition,” Human Molecular Genet-
ics, vol. 18, no. 2, pp. 304–317, 2009.
[62] D. B¨ aumer, O. Ansorge, M. Almeida, and K. Talbot, “The
role of RNA processing in the pathogenesis of motor neuron
degeneration,” Expert Reviews in Molecular Medicine, vol. 12,
p. e21, 2010.
[63] P. Corcia, W. Camu, J. Praline, P. H. Gordon, P. Vourch, and
C.Andres,“TheimportanceoftheSMNgenesinthegenetics
of sporadic ALS,” Amyotrophic Lateral Sclerosis, vol. 10, no. 5-
6, pp. 436–440, 2009.
[64] Y. Piao, T. Hashimoto, S. Takahama et al., “Survival motor
neuron (SMN) protein in the spinal anterior horn cells of
patients with sporadic amyotrophic lateral sclerosis,” Brain
Research, vol. 1372, pp. 152–159, 2011.
[65] M. Dejesus-Hernandez et al., “Expanded GGGGCC hex-
anucleotide repeat in noncoding region of C9ORF72 causes
chromosome 9p-linked FTD and ALS,” Neuron, vol. 72, no.
2, pp. 245–256, 2011.
[66] A. E. Renton et al., “A hexanucleotide repeat expansion in
C9ORF72 is the cause of chromosome 9p21-linked ALS-
FTD,” Neuron, vol. 72, no. 2, pp. 257–268, 2011.
[67] M. Wojciechowska and W. J. Krzyzosiak, “Cellular toxicity
of expanded RNA repeats: focus on RNA foci,” Human
Molecular Genetics, vol. 20, no. 19, pp. 3811–3821, 2011.
[68] G. Sicot, G. Gourdon, and M. Gomes-Pereira, “Myotonic
dystrophy, when simple repeats reveal complex pathogenic
entities: new ﬁndings and future challenges,” Human Molec-
ular Genetics, vol. 20, no. 2, pp. R116–R123, 2011.
[69] E. Buratti, A. Brindisi, M. Giombi, S. Tisminetzky, Y. M.
Ayala, and F. E. Baralle, “TDP-43 binds heterogeneous nu-
clear ribonucleoprotein A/B through its C-terminal tail: an
important region for the inhibition of cystic ﬁbrosis trans-
membrane conductance regulator exon 9 splicing,” The Jour-
nalofBiologicalChemistry,vol.280,no.45,pp.37572–37584,
2005.
[70] O. A. Sofola, P. Jin, Y. Qin et al., “RNA-binding proteins
hnRNP A2/B1 and CUGBP1 suppress fragile X CGG pre-
mutation repeat-induced neurodegeneration in a drosophila
model of FXTAS,” Neuron, vol. 55, no. 4, pp. 565–571, 2007.
[71] M. J. Hitchler and F. E. Domann, “An epigenetic perspective
on the free radical theory of development,” Free Radical
Biology and Medicine, vol. 43, no. 7, pp. 1023–1036, 2007.
[72] M. J. Hitchler and F. E. Domann, “Metabolic defects provide
a spark for the epigenetic switch in cancer,” Free Radical
Biology and Medicine, vol. 47, no. 2, pp. 115–127, 2009.
[73] B. Langley, M. A. D’Annibale, K. Suh et al., “Pulse inhibition
of histone deacetylases induces complete resistance to oxida-
tive death in cortical neurons without toxicity and reveals
a role for cytoplasmic p21waf1/cip1 in cell cycle-independent
neuroprotection,” Journal of Neuroscience, vol. 28, no. 1, pp.
163–176, 2008.
[74] K. Doyle and F. A. Fitzpatrick, “Redox signaling, alkylation
(carbonylation) of conserved cysteines inactivates class I
histone deacetylases 1, 2, and 3 and antagonizes their trans-
criptional repressor function,” The Journal of Biological
Chemistry, vol. 285, no. 23, pp. 17417–17424, 2010.
[75] J. Hnilicov´ a, S. Hozeiﬁ, E. Duˇ skov´ a ,J .I c h a ,T .T o m ´ ankov´ a,
and D. Stanˇ ek, “Histone deacetylase activity modulates
alternative splicing,” PLoS ONE, vol. 6, no. 2, 2011.
[76] I. Rahman, J. Marwick, and P. Kirkham, “Redox modulation
of chromatin remodeling: Impact on histone acetylation and
deacetylation, NF-κB and pro-inﬂammatory gene expres-
sion,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1255–
1267, 2004.
[77] Q. Li, C. V. Velde, A. Israelson et al., “ALS-linked mutant
superoxide dismutase 1 (SOD1) alters mitochondrial protein
composition and decreases protein import,” Proceedings of
the National Academy of Sciences of the United States of Amer-
ica, vol. 107, no. 49, pp. 21146–21151, 2010.
[78] D. Bergemalm, K. Forsberg, P. Andreas Jonsson et al.,
“Changes in the spinal cord proteome of an amyotrophic lat-
eral sclerosis murine model determined by diﬀerential in-
gel electrophoresis,” Molecular and Cellular Proteomics, vol.
8, no. 6, pp. 1306–1317, 2009.
[79] T. Massignan, F. Casoni, M. Basso et al., “Proteomic analysis
of spinal cord of presymptomatic amyotrophic lateral sclero-
sisG93ASOD1mouse,”BiochemicalandBiophysicalResearch
Communications, vol. 353, no. 3, pp. 719–725, 2007.
[80] A. Maracchioni, A. Totaro, D. F. Angelini et al., “Mitochon-
drial damage modulates alternative splicing in neuronal cells:
Implications for neurodegeneration,” Journal of Neurochem-
istry, vol. 100, no. 1, pp. 142–153, 2007.
[81] S. C. Lenzken, V. Romeo, F. Zolezzi et al., “Mutant SOD1 and
mitochondrial damage alter expression and splicing of genes
controlling neuritogenesis in models of neurodegeneration,”
Human Mutation, vol. 32, no. 2, pp. 168–182, 2011.
[82] A.Brunet,L.B.Sweeney,J.F.Sturgilletal.,“Stress-dependent
regulation of FOXO transcription factors by the SIRT1
deacetylase,”Science,vol.303,no.5666,pp.2011–2015,2004.
[83] Z. Lu, X. Xu, X. Hu et al., “PGC-1α regulates expression of
myocardial mitochondrial antioxidants and myocardial oxi-
dativestressafterchronicsystolicoverload,”Antioxidantsand
Redox Signaling, vol. 13, no. 7, pp. 1011–1022, 2010.
[84] K. Aquilano, P. Vigilanza, S. Baldelli, B. Pagliei, G. Rotilio,
and M. R. Ciriolo, “Peroxisome proliferator-activated recep-
tor γ co-activator 1 α (PGC-1α) and sirtuin 1 (SIRT1) reside
in mitochondria: possible direct function in mitochondrial
biogenesis,” The Journal of Biological Chemistry, vol. 285, no.
28, pp. 21590–21599, 2010.
[ 8 5 ]J .H .L i m ,Y .M .L e e ,Y .S .C h u n ,J .C h e n ,J .E .K i m ,a n dJ .
W. Park, “Sirtuin 1 modulates cellular responses to hypoxia
bydeacetylatinghypoxia-induciblefactor1alpha.,”Molecular
cell, vol. 38, no. 6, pp. 864–878, 2010.
[86] E. M. Dioum, R. Chen, M. S. Alexander et al., “Regulation of
hypoxia-induciblefactor2αsignalingbythestressresponsive
deacetylase sirtuin 1,” Science, vol. 324, no. 5932, pp. 1289–
1293, 2009.
[87] I. Mattagajasingh, C. S. Kim, A. Naqvi et al., “SIRT1 pro-
motes endothelium-dependent vascular relaxation by acti-
vating endothelial nitric oxide synthase,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 37, pp. 14855–14860, 2007.
[88] Y.Yang,W.Fu,J.Chenetal.,“SIRT1sumoylationregulatesits
deacetylase activity and cellular response to genotoxic stress,”
Nature Cell Biology, vol. 9, no. 11, pp. 1253–1262, 2007.
[89] M. K. Han, E. K. Song, Y. Guo, X. Ou, C. Mantel, and
H. E. Broxmeyer, “SIRT1 regulates apoptosis and Nanog
expression in mouse embryonic stem cells by controlling p53
subcellular localization,” Cell Stem Cell, vol. 2, no. 3, pp. 241–
251, 2008.International Journal of Cell Biology 9
[90] F. Wang, M. Nguyen, F. X. F. Qin, and Q. Tong, “SIRT2 dea-
cetylates FOXO3a in response to oxidative stress and caloric
restriction,” Aging Cell, vol. 6, no. 4, pp. 505–514, 2007.
[91] E. L. Bell, B. M. Emerling, S. J. H. Ricoult, and L. Guarente,
“SirT3 suppresses hypoxia inducible factor 1α and tumor
growth by inhibiting mitochondrial ROS production,” Onco-
gene, vol. 30, no. 26, pp. 2986–2996, 2011.
[92] R. Tao, M. C. Coleman, J. D. Pennington et al., “Sirt3-med-
iated deacetylation of evolutionarily conserved lysine 122
regulates MnSOD activity in response to stress,” Molecular
Cell, vol. 40, no. 6, pp. 893–904, 2010.
[93] Y. Chen, J. Zhang, Y. Lin et al., “Tumour suppressor SIRT3
deacetylates and activates manganese superoxide dismutase
to scavenge ROS,” EMBO Reports, vol. 12, no. 6, pp. 534–541,
2011.
[94] W. C. Hallows, W. Yu, B. C. Smith et al., “Sirt3 promotes the
ureacycleandfattyacidoxidationduringdietaryrestriction,”
Molecular Cell, vol. 41, no. 2, pp. 139–149, 2011.
[95] B. H. Ahn, H. S. Kim, S. Song et al., “A role for the mitochon-
drial deacetylase Sirt3 in regulating energy homeostasis,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 105, no. 38, pp. 14447–14452, 2008.
[96] D. B. Lombard, F. W. Alt, H. L. Cheng et al., “Mammalian
Sir2 homolog SIRT3 regulates global mitochondrial lysine
acetylation,” Molecular and Cellular Biology, vol. 27, no. 24,
pp. 8807–8814, 2007.
[97] S. Someya, W. Yu, W. C. Hallows et al., “Sirt3 mediates
reduction of oxidative damage and prevention of age-related
hearing loss under caloric restriction,” Cell, vol. 143, no. 5,
pp. 802–812, 2010.
[98] M. C. Haigis, R. Mostoslavsky, K. M. Haigis et al., “SIRT4
inhibits glutamate dehydrogenase and opposes the eﬀects of
calorie restriction in pancreatic β cells,” Cell, vol. 126, no. 5,
pp. 941–954, 2006.
[99] T. Nakagawa, D. J. Lomb, M. C. Haigis, and L. Guarente,
“SIRT5 deacetylates carbamoyl phosphate synthetase 1 and
regulates the urea cycle,” Cell, vol. 137, no. 3, pp. 560–570,
2009.
[100] L. Zhong, A. D’Urso, D. Toiber et al., “The histone deacety-
lase Sirt6 regulates glucose homeostasis via Hif1α,” Cell, vol.
140, no. 2, pp. 280–293, 2010.
[101] O. Vakhrusheva, C. Smolka, P. Gajawada et al., “Sirt7
increases stress resistance of cardiomyocytes and prevents
apoptosis and inﬂammatory cardiomyopathy in mice,” Cir-
culation Research, vol. 102, no. 6, pp. 703–710, 2008.
[102] L. G. Bilsland, E. Sahai, G. Kelly, M. Golding, L. Greensmith,
and G. Schiavo, “Deﬁcits in axonal transport precede ALS
symptoms in vivo,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 107, no. 47, pp.
20523–20528, 2010.